Trial Design

Results from the joint Phase III clinical trial of the vaccine also demonstrated results comparable to the companies’ licensed COVID-19 vaccine.

Tracking efforts to advance the mission and concept of "clinical research as a care option."

Q&A with Joachim Lövin explores the challenges and lessons learned in boosting the flexibility of conducting decentralized clinical trials post-COVID.

Results demonstrated prolonged progression free survival of two patients in Acclaim-1 study and partial remission from maintenance therapy in Acclaim-3 study.

Webinar Date/Time: Tuesday, August 27, 2024 at 11:00 AM EDT | 8:00 AM PDT | 4:00 PM BST | 5:00 PM CEST

Clinical trial for BI 3034701 is expected to evaluate the safety, tolerability, and pharmacokinetics in healthy men and overweight or obese individuals aged 18-55 years old.

Reportedly, data from the Vivacity-MG3 trial marks the first time an FcRn blocker demonstrated superiority over placebo in treated generalized myasthenia gravis (gMG).

A three-part framework for a more comprehensive conceptual model of patient experience data can provide a more rounded understanding of patient experiences in clinical trials and beyond.

Webinar Date/Time: Wed, Jul 17, 2024 1:00 PM EDT

Improved diversity in clinical trials can be achieved by exploring opportunities for research in developing countries that have not historically participated in large-scale, industry-sponsored clinical trials.

How making trial participation easier can reduce the impact on the environment.

New research updates estimated value of lost time.

Although executive enthusiasm for decentralization of clinical trials has grown significantly, operationalizing these models requires meticulous planning and risk-based quality management.

How artificial intelligence can aid in selecting patients, leveraging safety insights, and optimizing combination therapies.

Webinar Date/Time: Tuesday, June 25th, 2024 at 11am EDT|8am PDT|4pm BST|5pm CEST

Promising scientific advances are pacing oncology drug development.

The potential of PBPK modeling in answering key questions around these drugs.

How innovative trial designs and advanced imaging modalities can address the challenges of early drug development to optimize outcomes for patients with solid tumors.

Webinar Date/Time: Tuesday, May 21st, 2024 at 2pm PDT | 5pm EDT | 11pm CEST

A representative sample patient population that accurately reflects the overall population is vital to establish the safety and efficacy of a drug.

Harnessing these tools for successful integration and streamlining of processes.

Webinar Date/Time: Wednesday, May 22, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

The current clinical development model is shifting toward a generative AI-augmented proactive approach supported by real-world data for real time evidence.

Following a webinar on the use of a medical device in a migraine clinical trial, Mowlem caught up with ACT to discuss her biggest takeaways and what she is currently seeing in the digital trials space.

Webinar Date/Time: Tuesday, May 7th, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

Amplifying the size and diversity of participant pools in clinical trials enhances statistical power and increases the generalizability of study findings.

New and renewed approaches to improve chances of success in developing non-addictive drugs for chronic pain.

In light of scant published data from sponsors and contract research organizations on site activation and recruitment challenges following the COVID-19 pandemic, the primary objective of this research is to revisit the results of recruitment and retention tactics in studies conducted in 2012 and 2019.

Transparent and detailed communication throughout the research process is key for effectively recruiting and retaining patients for clinical trials.

The clinical research industry is increasingly leveraging insights, experience, and advanced solutions to better implement diversity and inclusion initiatives.